CD74 antibody (AA 1-232)

Catalog No. ABIN3031241

The Mouse Monoclonal anti-CD74 antibody has been validated for FACS, WB and ELISA. It is suitable to detect CD74 in samples from Human.

Quick Overview for CD74 antibody (AA 1-232) (ABIN3031241)

Target: CD74 (HLA-DR-gamma (CD74))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CD74 antibody is un-conjugated

Application: Flow Cytometry (FACS), Western Blotting (WB), ELISA

Clone: 1267CT820-116-140-154

Product Details anti-CD74 Antibody

Binding Specificity: AA 1-232

Purification: Purified

Immunogen: This CD74 antibody was produced from a mouse immunized with a KLH conjugated synthetic peptide between 1-232 amino acids from human protein.

Isotype: IgG2b kappa

Application Details

Application Notes: Titration of the CD74 antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Flow Cytometry: 1:25,Western blot: 1:1000

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: In 1X PBS, pH 7.4, with 0.09 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Aliquot the CD74 antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

Target Details for CD74

Target: CD74 (HLA-DR-gamma (CD74))

Alternative Name: CD74

Background: Plays a critical role in MHC class II antigen processing by stabilizing peptide-free class II alpha/beta heterodimers in a complex soon after their synthesis and directing transport of the complex from the endoplasmic reticulum to the endosomal/lysosomal system where the antigen processing and binding of antigenic peptides to MHC class II takes place. Serves as cell surface receptor for the cytokine MIF.

UniProt: P04233

Pathways: Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Negative Regulation of intrinsic apoptotic Signaling, Cancer Immune Checkpoints